Literature DB >> 2037540

Inhibition of Legionella pneumophila in guinea pig peritoneal macrophages by new quinolone, macrolide and other antimicrobial agents.

K Kitsukawa1, J Hara, A Saito.   

Abstract

The effect of 14 antimicrobial agents, including new quinolones and a new macrolide, on the intracellular multiplication of Legionella pneumophila in cultured guinea pig peritoneal macrophages was examined. Gentamicin and beta-lactam antibiotics did not inhibit the intracellular growth of L. pneumophila. Minocycline, erythromycin and DR-3355 inhibited multiplication at concentrations of 1, 0.5 and 0.1 mg/l respectively. Rifampicin, the new macrolide roxithromycin, and the new quinolones ofloxacin, ciprofloxacin and AT-4140 all inhibited the intracellular growth of L. pneumophila at concentrations of less than 0.03 mg/l. The minimal extracellular concentration inhibiting intracellular multiplication (MIEC), compared with conventional MIC measurements, provides a better indication of antimicrobial efficacy against bacteria, such as L. pneumophila, which can multiply in phagocytes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2037540     DOI: 10.1093/jac/27.3.343

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

1.  Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species.

Authors:  D M Johnson; M E Erwin; M S Barrett; B B Gooding; R N Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

2.  In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

3.  Comparison of charcoal- and starch-based media for testing susceptibilities of Legionella species to macrolides, azalides, and fluoroquinolones.

Authors:  S L Pendland; S J Martin; C Chen; P C Schreckenberger; L H Danziger
Journal:  J Clin Microbiol       Date:  1997-11       Impact factor: 5.948

4.  Simplified quantitative assay system for measuring activities of drugs against intracellular Legionella pneumophila.

Authors:  F Higa; N Kusano; M Tateyama; T Shinzato; N Arakaki; K Kawakami; A Saito
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

5.  Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila.

Authors:  A L Baltch; R P Smith; W Ritz
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

6.  In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; T Shinzato; E Doyle; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

7.  In vitro extracellular and intracellular activities of clavulanic acid and those of piperacillin and ceftriaxone alone and in combination with tazobactam against clinical isolates of Legionella species.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

8.  Uptake of cefepime by phagocytosing polymorphonuclear neutrophils and subsequent intracellular killing.

Authors:  H Pruul; P J McDonald
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

Review 9.  Quinolones in the treatment of lower respiratory tract infections caused by intracellular pathogens.

Authors:  C Chidiac; Y Mouton
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 10.  Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.

Authors:  K L Goa; H M Bryson; A Markham
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.